



0 30

MT  
7-16-96  
#24

**In re Application of:**

DOUGLAS N. ISHII

**Serial No.: 08/571,802**

Filed: December 13, 1995

**For: METHOD FOR EFFECTING CHANGES  
IN THE CENTRAL NERVOUS SYSTEM  
BY ADMINISTRATION OF IGF-I OR  
IGF-II**

**Group Art Unit:**

**Examiner:**

Attorney Docket: CSUA019/WAA

RECEIVED  
JUN 14 1996  
GROUP 1800

## INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant respectfully requests that this Information Disclosure Statement be entered and the references listed on the attached PTO-1449 form be considered by the examiner and made of record. Copies of the listed references A1 to A47 were previously made of record in the United States Patent and Trademark Office in the following applications upon which Applicant relies under 35 U.S.C. § 120 for an earlier filing date:


U.S. Patent Application Serial No.: 08/398,852  
Applicants: DOUGLAS N. ISHII  
Filed: March 6, 1995  
For: METHOD FOR TREATING DIABETIC NEUROPATHY WITH  
IGF-I OR IGF-II (Amended Title)

U.S. Patent Application Serial No.: 07/909,200  
Applicants: DOUGLAS N. ISHII  
Filed: July 6, 1992  
For: METHOD OF TREATING NEURAL DISORDERS

Copies of the listed references A48 to A62 are enclosed.

This Information Disclosure Statement is being submitted prior to receipt of a first Office Action. If a first Office Action has been mailed prior to the filing of this Information Disclosure Statement, the Commissioner is authorized to charge Account No. 01-2508, Order No. CSUA019/WAA, \$200 for the requisite fee.

Respectfully submitted,



Janelle D. Waack  
Reg. No. 36,300

ATTORNEY FOR ASSIGNEE,  
COLORADO STATE UNIVERSITY  
RESEARCH FOUNDATION

ARNOLD, WHITE & DURKEE  
P. O. Box 4433  
Houston, Texas 77210-4433  
(713) 787-1686

March 29, 1996

Serial No. 08/571,802  
Information Disclosure Statement